Case report details repigmentation after stopping melanotan use in a patient with skin and hair disorders, highlighting paradoxical effects.
Melanotan analogues are increasingly associated with pigmentary adverse effects. We report vitiligo-like depigmentation following melanotan use in a patient with atopic dermatitis and alopecia areata, with repigmentation after discontinuation. This case highlights a paradoxical response and the importance of identifying unregulated peptide use in new-onset depigmentation.
No takes yet. Share an insight, caveat, or question.
Ume et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: